The earnings call highlighted significant revenue growth, strong performance of key products, and multiple regulatory approvals, indicating positive business momentum. However, high operating expenses and non-cash charges were noted as challenges.

Company Guidance -

Q3 2025

In the recent call, Mirum Pharmaceuticals provided updated guidance for the fiscal year 2025 following a record-breaking first quarter. The company reported total revenues of $111.6 million, representing a 61% growth over the same period last year. As a result of robust growth from their commercial medicines, Mirum raised its full-year revenue guidance to between $435 million and $450 million. Key drivers included strong sales of LIVMARLI, which saw global net product sales reach $73.2 million, a growth of over 70% compared to the first quarter of 2024. U.S. sales of LIVMARLI were $49.5 million, highlighting strong new patient demand. Additionally, Mirum achieved three regulatory approvals since the beginning of the year, further bolstering its growth prospects. The company also reported that it was cash flow positive for the quarter, with a cash, cash equivalents, and investments balance of $298.6 million as of March 31st, 2025.

Record-Breaking Revenue Growth

Mirum Pharmaceuticals reported total revenues of $111.6 million for Q1 2025, representing a 61% growth over the first quarter of the previous year.

Updated Revenue Guidance

The company increased its full-year revenue guidance to $435 million to $450 million, driven by robust growth across its commercial medicines.

Regulatory Approvals

Three important regulatory approvals were received, including FDA approval of CTEXLI for CTX treatment and LIVMARLI's approval in Japan for PFIC and Alagille syndrome.

Strong Performance of LIVMARLI

Total global net product sales for LIVMARLI grew to $73.2 million in Q1, an increase of over 70% compared to Q1 2024.

Pipeline Progress

The VISTAS study of Volixibat in PSC is nearing enrollment completion, with top-line data expected in Q2 2026. The VANTAGE study in PBC showed a 3.8 point reduction from baseline in pruritus.

Improved Financial Position

Operating cash flow was positive for the quarter, with a cash contribution margin improvement from approximately 47% to 53% year-over-year.

Mirum Pharmaceuticals (MIRM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MIRM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.18 / -	-0.3	―	―	―
Aug 06, 2025	2025 (Q2)	-0.33 / -0.12	-0.52	76.92% (+0.40)	―
May 07, 2025	2025 (Q1)	-0.33 / -0.30	-0.54	44.44% (+0.24)	―
Feb 26, 2025	2024 (Q4)	-0.26 / -0.49	-0.63	22.22% (+0.14)
Nov 12, 2024	2024 (Q3)	-0.45 / -0.30	-0.57	47.37% (+0.27)
Aug 07, 2024	2024 (Q2)	-0.47 / -0.52	-1.94	73.20% (+1.42)	―
May 08, 2024	2024 (Q1)	-0.42 / -0.54	-0.8	32.50% (+0.26)	―
Feb 28, 2024	2023 (Q4)	-0.24 / -0.63	-0.99	36.36% (+0.36)
Nov 02, 2023	2023 (Q3)	-0.63 / -0.57	-1.02	44.12% (+0.45)
Aug 03, 2023	2023 (Q2)	-0.80 / -1.94	-0.84	-130.95% (-1.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MIRM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$41.22	$45.24	+9.75%
Feb 26, 2025	$50.52	$46.98	-7.01%
Nov 12, 2024	$41.61	$42.28	+1.61%
Aug 07, 2024	$38.96	$39.87	+2.34%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mirum Pharmaceuticals (MIRM) report earnings?

Mirum Pharmaceuticals (MIRM) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is Mirum Pharmaceuticals (MIRM) earnings time?

Mirum Pharmaceuticals (MIRM) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MIRM EPS forecast?

MIRM EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing